The roles and implications of RNA m6A modification in cancer

X Deng, Y Qing, D Horne, H Huang… - Nature Reviews Clinical …, 2023 - nature.com
Abstract N 6-Methyladenosine (m6A), the most prevalent internal modification in eukaryotic
mRNA, has been extensively and increasingly studied over the past decade. Dysregulation …

[HTML][HTML] The IGF2BP family of RNA binding proteins links epitranscriptomics to cancer

D Ramesh-Kumar, S Guil - Seminars in Cancer Biology, 2022 - Elsevier
RNA binding proteins that act at the post-transcriptional level display a richness of
mechanisms to modulate the transcriptional output and respond to changing cellular …

Oncofetal protein IGF2BPs in human cancer: functions, mechanisms and therapeutic potential

TY Zhu, LL Hong, ZQ Ling - Biomarker research, 2023 - Springer
Abstract N6-methyladenosine (m6A) is the most prevalent and well-characterized internal
chemical modification in eukaryotic RNA, influencing gene expression and phenotypic …

IGF2BP1 regulates the cargo of extracellular vesicles and promotes neuroblastoma metastasis

MR Dhamdhere, CP Gowda, V Singh, Z Liu… - Oncogene, 2023 - nature.com
Neuroblastoma is a highly metastatic cancer, and thus is one of the leading causes of
cancer-related mortalities in pediatric patients. More than 50% of NB cases exhibit 17q21-ter …

RNA-binding proteins in cancer drug discovery

JB Bertoldo, S Müller, S Hüttelmaier - Drug discovery today, 2023 - Elsevier
Highlights•RNA-binding proteins (RBPs) are essential for tumorigenesis, immune evasion,
invasion, migration and metastasis, hence promising drug targets in cancer therapy.•Small …

[HTML][HTML] Regulatory mechanisms and therapeutic implications of insulin-like growth factor 2 mRNA-binding proteins, the emerging crucial m6A regulators of tumors

H Zhou, Q Sun, M Feng, Z Gao, S Jia, L Cao, X Yu… - Theranostics, 2023 - ncbi.nlm.nih.gov
Insulin-like growth factor 2 mRNA-binding proteins (IGF2BPs) serve essential biological
functions as post-transcriptional performers, participating in the acquisition or maintenance …

RNA m6A methylation in cancer

Z Wang, J Zhou, H Zhang, L Ge, J Li… - Molecular …, 2023 - Wiley Online Library
N 6‐methyladenosine (m6A) is one of the most abundant internal modifications in eukaryotic
messenger RNAs (mRNAs) and non‐coding RNAs (ncRNAs). It is a reversible and dynamic …

Extracellular Vesicle (EVs) associated non-coding RNAs in lung cancer and therapeutics

A Paramanantham, R Asfiya, S Das, G McCully… - International journal of …, 2022 - mdpi.com
Lung cancer is one of the most lethal forms of cancer, with a very high mortality rate. The
precise pathophysiology of lung cancer is not well understood, and pertinent information …

Regulation of m6A modification on ferroptosis and its potential significance in radiosensitization

X Chen, L Zhang, Y He, S Huang, S Chen… - Cell Death …, 2023 - nature.com
Radiotherapy is often used to treat various types of cancers, but radioresistance greatly
limits the clinical efficiency. Recent studies have shown that radiotherapy can lead to …

[HTML][HTML] IGF2BPs as novel m6A readers: Diverse roles in regulating cancer cell biological functions, hypoxia adaptation, metabolism, and immunosuppressive tumor …

M Duan, H Liu, S Xu, Z Yang, F Zhang, G Wang… - Genes & diseases, 2024 - Elsevier
Abstract m 6 A methylation is the most frequent modification of mRNA in eukaryotes and
plays a crucial role in cancer progression by regulating biological functions. Insulin-like …